Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06353828
Other study ID # ICBD-UC-01
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date March 1, 2023
Est. completion date April 1, 2025

Study information

Verified date March 2024
Source CannaMore Biotechs
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ulcerative proctitis can lead to considerable morbidity, and the available treatment options are limited. Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa, possesses potent immunomodulatory and anti-inflammatory properties as described in both acute and chronic animal models of inflammation, including IBD models. Based on positive safety and initial efficacy profiles of CBD found in IBD animal and clinical studies, the main aim of this study is to evaluate the safety, tolerability and efficacy of a novel enema formulation of CBD for the treatment of active ulcerative proctitis.


Description:

This study consists of 2 stages: Stage 1. Feasibility - Open label stage: Up to fourteen patients will be enrolled in this stage and receive a CBD enema formulation for 12 weeks treatment period. If results of this stage prove to be safe and with clinical effect (reduction of 3 points in full Mayo score in at least 50% of patients), the study will proceed to stage 2. Stage 2. Randomized, placebo controlled blinded stage: Subjects will be randomized in a 2:1 ratio and receive the drug/placebo enema for a 12 weeks treatment period. Patients will be assessed for full Mayo score on visit 1 and week 12, and partial Mayo score every visit. Patients will assessed by a clinician using the self reported outcome (PRO) scale every visit. Sigmoidoscopy will be performed at baseline and week 12.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 45
Est. completion date April 1, 2025
Est. primary completion date April 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years 2. Diagnosis of UC at least 3 months prior to the Screening Visit 3. Patients who were not treated rectally for UC in the last 3 days. 4. UC patients with active disease and being treated with stable doses of biologics (at least 2 months), and/or steroids (at least 1 months) and/or oral mesalazine (at least 2 months at stable dose (4 gr)) or non-treated patients) 5. Full Mayo score =4 to < 9 (range: 0-12) prior to enrolment in the study 6. Patients that did not respond to Mesalamine treatment. 7. Non-pregnant (via negative pregnancy test)/non-breast-feeding women and women with no intention to become pregnant/to breast-feed during the term of the trial and for at least one month after cessation of IcBD-01 treatment 8. Male subject with female partner(s) of child-bearing potential (including breastfeeding partner[s]) must agree to use contraception throughout the treatment period and for one month after final IMP administration. 9. Subject able to provide written informed consent 10. Must be able to adhere to the study visit schedule and other protocol requirements Exclusion Criteria: 1. Diagnosis of severe extensive pancolitis 2. Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis, or diverticular disease-associated colitis 3. Complete resection of the colon with the need of a pouch 4. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis, atypical mycobacterial disease, and herpes zoster), human immunodeficiency virus (HIV), or any major episode of infection requiring hospitalization or treatment with intravenous (IV) or oral antibiotics within 4 weeks of screening 5. Sexual transmitted diseases 6. Using rectal formulations (such as Mesalazine) for the last 3 days 7. Subjects who have received any investigational drug or used investigational device in the last 2 months 8. Serious psychiatric or psychological disorders 9. Active consumption of illicit drugs including cannabis or derivatives for at least 1 months prior to the study 10. Patients with short bowel syndrome, symptomatic stricture, abscess, recent history (within the previous 3 months) of abdominal surgery 11. Patients with significant cardiac, hepatic, respiratory disease comorbidities or active malignancy 12. Renal comorbidity: eGFR< 30 mL/min/1.73 m2 (note: CKD Grade 4 is defined as eGFR 15-29 mL/min/1.73 m2) 13. Patient who is taking immunomodulatory medications for other indication(s) 14. Women of child-bearing potential who intend to become pregnant or who are pregnant or breastfeeding or male subjects with female partners who intend to get pregnant or breastfeed during the trial period

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CBD, synthetic form
Cannabidiol enema
Placebo
placebo enema

Locations

Country Name City State
Israel Meir Medical Center Kfar Saba

Sponsors (1)

Lead Sponsor Collaborator
CannaMore Biotechs

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in Full Mayo Score The Mayo Score is used to assess the severity of ulcerative colitis and can range from 0-12, with higher scores indicating worse severity. 12 weeks
Secondary Change in Partial Mayo Score The partial Mayo Score is used to assess the severity of UC and does not include the endoscopic parameter. Can range from 0-9, with higher scores indicating worse severity. 12 weeks
Secondary Change in patient reported outcome (PRO-UC) PRO-UC Diary is a tool to quantify the patient perspective in terms of how they feel and function. Can range from 0-20, with higher scores indicating worse severity 12 weeks
Secondary Change in endoscopic Mayo subscore in distal 15 cm of anus Efficacy will be determined through the use of the Mayo Endoscopic Subscore. 12 weeks
Secondary Change in the length of the inflamed colon Length of inflamed colon (Mayo subscore) will be measured through endoscopy 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2